On May 30, 2023 AstraZeneca and Kiyatec, the leader in clinically correlated functional precision oncology, reported to have entered into a multifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical assets using Kiyatec’s 3D spheroid screening platform, KIYA-PredictTM (Press release, AstraZeneca, MAY 30, 2023, View Source [SID1234632236]). The agreement to utilize Kiyatec’s spheroid platform aligns with AstraZeneca’s leadership and track record of successfully implementing novel, cutting edge oncology solutions with outside partners to productively develop and commercialize novel cancer therapeutics.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kiyatec’s proprietary spheroid platform successfully utilizes primary human tumor tissues, enabling a research strategy that takes advantage of the company’s ability to properly dissociate and characterize primary patient tissues and accurately determine therapeutic efficacy across multiple downstream assays. Importantly, a strong correlation between platform generated results and clinical outcomes has been demonstrated and published. With established clinical correlation, functional precision medicine platforms such as Kiyatec’s can help to provide crucial translational oncology data that supports clinical candidate selection, and ultimately helps to avoid efficacy failures later in the clinic.
This type of research agreement is a model for the entire oncology community by coupling crucial programs to reduce or avoid failures within the clinic due to lack of accurate translational models. Platforms such as Kiyatec’s KIYA-PredictTM that can offer a high degree of clinical correlations are powerful tools for all modalities of therapeutics to ensure accurate translational efficacy. Entering into this agreement with AstraZeneca continues to strengthen Kiyatec’s commitment to supporting biopharma’s oncology programs, and ultimately provide further validation as a global leader in functional precision medicine within the translational oncology drug discovery space.